AIM
RPRX

Alambic Investment Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Alambic Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,091
Closed -$21K – 731
2016
Q4 		$21K Buy
+16,091
New +$28K ﹤0.01% 561
2016
Q3 		– Sell
-69,191
Closed -$111K – 604
2016
Q2 		$111K Sell
69,191
-45,400
-40% -$87.1K 0.03% 493
2016
Q1 		$111K Sell
114,591
-55,909
-33% -$54.5K 0.04% 440
2015
Q4 		$206K Buy
+170,500
New +$547K 0.12% 276

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Alambic Investment Management's RPRX Position: Q1 2017 in Review

Alambic Investment Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 16,091 shares — an estimated $21K sold.

Alambic Investment Management first reported a position in RPRX in Q4 2015 and held it in 4 quarters. The position peaked at $206K in Q4 2015. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

  • Alambic Investment Management reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
  • Alambic Investment Management sold 16,091 Repros Therapeutics Inc. shares in Q1 2017, an estimated $21K.
  • Alambic Investment Management first reported a position in Repros Therapeutics Inc. in Q4 2015 and held it in 4 quarters.
  • Alambic Investment Management's Repros Therapeutics Inc. position peaked at $206K in Q4 2015.
  • 33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Alambic Investment Management's 13F filing for Q1 2017, filed 9 May 2017.